Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Mechanical heart valve prosthesis and warfarin - Treatment quality and prognosis.

Grzymala-Lubanski, Bartosz ; Labaf, Ashkan LU ; Englund, Erling ; Svensson, Peter LU and Själander, Anders (2014) In Thrombosis Research 133(5). p.795-798
Abstract
Every year about 2500 patients in Sweden undergo surgery due to heart valve disease. A mechanical heart valve prosthesis causes risk of thromboembolic stroke or thrombus formation in the valve while anticoagulant treatment increases the risk of bleeding. Treatment quality with warfarin is crucial for patients with mechanical valve prostheses. It has previously been shown that poorly controlled warfarin treatment increases mortality in this patient group. TTR (Time in Therapeutic Range) on warfarin has been shown to affect the risk of complications in atrial fibrillation, but has not been studied in patients with mechanical heart valves. Our aim is to evaluate the impact of TTR on the risk of complications in this patient group.
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Thrombosis Research
volume
133
issue
5
pages
795 - 798
publisher
Elsevier
external identifiers
  • pmid:24642005
  • wos:000334739100017
  • scopus:84898778022
  • pmid:24642005
ISSN
1879-2472
DOI
10.1016/j.thromres.2014.02.031
language
English
LU publication?
yes
id
6c59609b-602f-4087-a0ce-8ccd1e347c38 (old id 4383030)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24642005?dopt=Abstract
date added to LUP
2016-04-01 11:15:58
date last changed
2022-04-28 08:34:34
@article{6c59609b-602f-4087-a0ce-8ccd1e347c38,
  abstract     = {{Every year about 2500 patients in Sweden undergo surgery due to heart valve disease. A mechanical heart valve prosthesis causes risk of thromboembolic stroke or thrombus formation in the valve while anticoagulant treatment increases the risk of bleeding. Treatment quality with warfarin is crucial for patients with mechanical valve prostheses. It has previously been shown that poorly controlled warfarin treatment increases mortality in this patient group. TTR (Time in Therapeutic Range) on warfarin has been shown to affect the risk of complications in atrial fibrillation, but has not been studied in patients with mechanical heart valves. Our aim is to evaluate the impact of TTR on the risk of complications in this patient group.}},
  author       = {{Grzymala-Lubanski, Bartosz and Labaf, Ashkan and Englund, Erling and Svensson, Peter and Själander, Anders}},
  issn         = {{1879-2472}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{795--798}},
  publisher    = {{Elsevier}},
  series       = {{Thrombosis Research}},
  title        = {{Mechanical heart valve prosthesis and warfarin - Treatment quality and prognosis.}},
  url          = {{http://dx.doi.org/10.1016/j.thromres.2014.02.031}},
  doi          = {{10.1016/j.thromres.2014.02.031}},
  volume       = {{133}},
  year         = {{2014}},
}